Overview
The Global Traditional Chinese Supplements Market (https://market.us/report/traditional-chinese-supplements-market/)is expected to grow from USD 28.3 billion in 2025 to USD 54.7 billion by 2035, at a CAGR of 6.8%. Asia Pacific leads the market with over 45.3% share, generating USD 12.83 billion in revenue in 2025.
Traditional Chinese Supplements (TCS) are herbal and botanical products used to support immunity, digestion, cardiovascular health, and overall wellness. Market growth is driven by rising chronic diseases, an aging population, and increasing preventive healthcare. In China, diabetes prevalence is projected to rise from 8.2% to 9.7%, while life expectancy exceeds 77 years, encouraging 300+ million older consumers to adopt TCM supplements. Rising disposable incomes, stronger post-pandemic immunity awareness, and growing acceptance of plant-based remedies in North America and Europe continue to support market expansion.
Key Takeaways
- The global Traditional Chinese Supplements market size was USD 28.3 billion in 2025.
- The global Traditional Chinese Supplements market size is estimated to grow to USD 54.7 billion by 2035.
- The Compound Annual Growth Rate (CAGR) of the market from 2026 to 2035 will be at 6.83%.
- Based on the type segment, the market share for Dietary Supplements stood at 51.3% of the total type segment.
- Based on the form segment, the Capsules & Tablets segment contributed to 48.0% of the form segment.
- Based on the application segment, the leading application category was the General Wellness & Immunity segment, contributing to 45.6% of the total application revenue.
- Based on the end-user segment, the Hospitals sub-category holds a market share of 46.3% as a result of clinical applications of supplements based on traditional Chinese medicine.
- The leading regional market is the Asia Pacific, with a market share of 45.3% of total global revenue. Type Analysis Dietary Supplements dominated the Traditional Chinese Supplements Market with a 51.3% share, supported by growing demand for immunity, heart health, metabolism, and anti-aging products. BYHEALTH Co., Ltd. reported that its TCM-based dietary supplements generated around 60% of total sales revenue in 2024. Specialty Supplements accounted for 20.3%, followed by Body Building Supplements (14.8%), Eye Health Supplements (7.2%), and Others (6.4%). Form Analysis Capsules & Tablets held the largest share at 48.0%, driven by standardized dosage, long shelf life, and regulatory acceptance. Powders & Granules captured 23.6% and recorded the fastest growth, with Infinitus (Hong Kong) Company Ltd. selling over 2 million units of its Astragalus-Reishi granules within six months in 2024. Liquids represented 17.2%, while Others accounted for 11.2%. Application Analysis General Wellness & Immunity led the market with a 45.6% revenue share, supported by rising preventive healthcare demand. Eu Yan Sang International Ltd. generated around 55% of its retail revenue from wellness and immunity products. Cardiology and Digestive & Liver Health were the fastest-growing applications, while a 2024 China study found Danshen-based formulations reduced cardiovascular risk markers by 28% over 12 weeks. End-User Analysis Hospitals accounted for 46.3% of market revenue, with nearly 95% of China's state-owned hospitals operating TCM departments. Clinics and Research Centers were the fastest-growing end-user segment, and over 350 integrative medicine clinics in the U.S. spent USD 45 million on Traditional Chinese Supplements in 2024. Key Market Segments By Type
- Dietary Supplement
- Body Building Supplements
- Eye Health Supplements
- Specialty Supplements
- Others By Form
- Capsules & Tablets
- Powders & Granules
- Liquids
- Others By Application
- Cardiology
- General Wellness & Immunity
- Digestive & Liver Health
- Others By End-User
- Hospitals
- Clinics
- Research Centers
- Other Opportunities China's aging population presents a major opportunity for silver-care supplement bundles. The country had 297 million people aged 60+ and 217 million aged 65+ at the end of 2023. Converting just 3%–4% of the 65+ population with annual spending of US$180–US$260 could create an additional US$1.2–US$2.3 billion revenue opportunity, improve customer retention by 12–18 percentage points, reduce acquisition costs by 20%–30%, and add an estimated 2.4 percentage points to CAGR. Challenges Regulatory complexity continues to slow market expansion despite improved approval processes in China. Product launches can be delayed by 12–24 months, reducing annual launch activity by 15%–25%. Decree No. 280, effective June 2026, introduces stricter registration requirements for overseas manufacturers, requiring brands to manage 3–5 regulatory pathways per product family. Compliance costs account for 8%–12% of total SG&A, creating an estimated 1.8 percentage-point drag on CAGR, although this is expected to ease within 2–4 years as regulations become more standardized. Drivers China's aging population is a key growth driver, with 323.38 million people aged 60+ (23% of the population) and 223.65 million aged 65+ by the end of 2025. The 60+ population is expected to exceed 400 million by 2035, increasing annual purchase frequency from 2.1 to 3.4 times and raising spending per elderly consumer by RMB 180–420, supporting an estimated 2.3 percentage-point increase in baseline CAGR. Restraints Imported product registration remains a major challenge despite China approving 2,130 health-food registrations in 2025 after an eight-year pause. Imported supplements typically require 12–24 months longer for approval, reducing first two-year IRR by 400–900 basis points per SKU. For portfolios of 20–30 launches, this could delay RMB 50–150 million in annual sales and reduce the 2026 baseline CAGR by an estimated 2.2 percentage points.
Top comments (0)